SILO PHARMA, INC. — Net Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/84229597-8fb3-466d-ab62-8211852ad6b4/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-4.2M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-035576 |
| FY 2024 | $-4.4M | 2024-01-01 – 2024-12-31 | evidence 0001013762-25-004139 |
| FY 2023 | $-3.7M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-025615 |
| FY 2022 | $-3.9M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-022813 |
| FY 2021 | $3.9M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-015521 |
| FY 2020 | $-3.0M | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-018270 |
| FY 2019 | $-1.0M | 2019-01-01 – 2019-12-31 | evidence 0001213900-20-007000 |
| FY 2018 | $-969.5k | 2018-01-01 – 2018-12-31 | evidence 0001213900-19-005789 |
| FY 2017 | $356.5k | 2017-01-01 – 2017-12-31 | evidence 0001213900-19-005789 |
| FY 2013 | $-1.2M | 2010-07-14 – 2013-09-30 | evidence 0001213900-13-006399 |
| FY 2012 | $-1.2M | 2010-07-13 – 2013-03-31 | evidence 0001213900-13-002541 |
| FY 2011 | $-49.8k | 2011-01-01 – 2011-12-31 | evidence 0001213900-13-000946 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).